Table 4.

Results of esophageal melanoma genotyping including Sanger sequencing of BRAF, KIT, and NRAS (15 cases) and all mutations identified by the Ion Torrent™ next-generation sequencing with Ion AmpliSeq™ Cancer Hotspot Panel v2 Kit (five cases) and Ion AmpliSeq™ Comprehensive Cancer Panel (three cases)

		Gene
Case	Methods	ATR	BRAF	CDKN2B	FBXW7	KIT	KRAS	NRAS	MTOR	SF3B1	TSC1
1	Ion AmpliSeq™ CCP Sanger sequencing	WT	WT	WT	WT	WT	WT	WT	WT	WT	p.H371Q
3	Sanger sequencing		WT			WT		WT
5	Sanger sequencing		WT			WT		WT
6	Ion AmpliSeq™ CHP Sanger sequencing	NIP	WT		WT	WT	WT	p.Q61K	NIP	NIP	NIP
7	Ion AmpliSeq™ CHP Sanger sequencing	NIP	WT	NIP	p.R479G	WT	WT	WT	NIP	NIP	NIP
8	Ion AmpliSeq™ CHP Sanger sequencing	NIP	WT	NIP	WT	WT	WT	p.A146T	NIP	NIP	NIP
9	Ion AmpliSeq™ CHP Sanger sequencing	NIP	WT	NIP	WT	WT	WT	p.Q61K	NIP	NIP	NIP
10	Sanger sequencing		WT			WT		WT
11	Sanger sequencing		WT			WT		WT
12	Ion AmpliSeq™ CCP Sanger sequencing	WT	WT	WT	WT	WT	WT	WT	p.Q1684*	p.R625C	WT
14	Ion AmpliSeq™ CHP Sanger sequencing	NIP	WT	NIP	p.R465C	WT	p.G13C	WT	NIP	NIP	NIP
16	Sanger sequencing		WT			WT		p.Q61H
17	Sanger sequencing		WT			WT		WT
19	Sanger sequencing		WT			WT		WT
20	Ion AmpliSeq™ CCP Sanger sequencing	p.V372G	WT	p.D110N	WT	xp.L576P	WT	xxp.Q61K	WT	p.K666T	WT

Complete next-generation sequencing data are provided in the Supplemental Table 2 and Supplemental Table 3

CCP Comprehensive Cancer Panel (409 gene targets), CHP Cancer Hotspot Panel v2 Kit (50 gene targets), NIP not included in this panel

^xnext-generation sequencing result

^xxSanger sequencing result